Valuation: Adocia

Market Cap 7.17Cr 8.28Cr 6.78Cr 6.14Cr 12Cr 793.9Cr 12Cr 81Cr 31Cr 402.55Cr 31Cr 30Cr 1.28TCr P/E 2026 *
-669x
P/E 2027 * 5.3x
Enterprise Value 4.18Cr 4.83Cr 3.96Cr 3.58Cr 6.72Cr 463.41Cr 6.77Cr 47Cr 18Cr 234.97Cr 18Cr 18Cr 749.37Cr EV / Sales 2026 *
16.6x
EV / Sales 2027 * 2.88x
Free-Float
96.05%
Yield 2026 *
-
Yield 2027 * -
1 week-6.27%
Current month-8.25%
1 month-11.63%
3 months-18.21%
6 months-37.99%
Current year-42.76%
1 week 3.48
Extreme 3.48
3.94
1 month 3.48
Extreme 3.48
4.26
3 years 3
Extreme 2.995
12.32
5 years 2.72
Extreme 2.725
14.84
10 years 2.72
Extreme 2.725
62.21
Manager TitleAgeSince
Chief Executive Officer 55 11/05/2023
Director of Finance/CFO - 23/09/2024
Chief Tech/Sci/R&D Officer - 01/12/2014
Director TitleAgeSince
Director/Board Member 55 19/04/2013
Chairman 57 -
Director/Board Member 61 11/05/2023
Change 5-day change 1-year change 3-year change Capi.($)
-0.49%-10.16%-55.54%-66.05% 8.28Cr
-1.38%+0.20%+46.42%+96.33% 6.92TCr
-0.40%-1.13%+35.65%+75.22% 6.2TCr
-4.29%-3.98%-16.22%+350.66% 2.62TCr
+1.46%+2.25%+28.84%+14.54% 2.57TCr
-2.20%-2.00%-1.22%-14.48% 2.43TCr
+3.91%+4.50%+25.67%-14.33% 1.98TCr
+1.26%-14.23%+170.04%+298.75% 1.57TCr
-5.54%+0.69%-8.13%+830.48% 1.39TCr
-0.39%-4.24%-9.86%+454.94% 1.41TCr
Average -0.84%-2.20%+21.57%+202.61% 3.01TCr
Weighted average by Cap. -0.86%-1.32%+31.83%+158.17%

Financials

2026 *2027 *
Net sales 25.22L 29.11L 23.84L 21.59L 40.51L 28Cr 40.82L 2.85Cr 1.09Cr 14Cr 1.09Cr 1.07Cr 45Cr 3.54Cr 4.09Cr 3.35Cr 3.03Cr 5.69Cr 392.03Cr 5.73Cr 40Cr 15Cr 198.78Cr 15Cr 15Cr 633.94Cr
Net income -43.17L -49.84L -40.82L -36.96L -69.36L -48Cr -69.88L -4.87Cr -1.87Cr -24Cr -1.87Cr -1.83Cr -77Cr -4.43Cr -5.12Cr -4.19Cr -3.79Cr -7.12Cr -490.89Cr -7.18Cr -50Cr -19Cr -248.91Cr -19Cr -19Cr -793.81Cr
Net Debt -2.98Cr -3.45Cr -2.82Cr -2.55Cr -4.79Cr -330.49Cr -4.83Cr -34Cr -13Cr -167.58Cr -13Cr -13Cr -534.43Cr 3.02Cr 3.48Cr 2.85Cr 2.58Cr 4.85Cr 334.18Cr 4.88Cr 34Cr 13Cr 169.45Cr 13Cr 13Cr 540.39Cr
Logo Adocia
Adocia is a biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins for the treatment of diabetes. At the end of 2025, the group had a portfolio of 4 products in clinical development (BioChaperone Lispro U100 and U200, BioChaperone Combo, M1Pram and BioChaperone Glucagon) and 4 preclinical-stage products (AdoShell® Islets, AdOral® Sema, AdoGel® Sema and BioChaperone® CagriSema).
Employees
-
Date Price Change
16/26/16 3.640 -0.16%
15/26/15 €3.646 +3.05%
14/26/14 €3.538 -2.53%
11/26/11 €3.630 -3.71%
10/26/10 €3.770 -2.38%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.664EUR
Average target price
9.700EUR
Spread / Average Target
+164.74%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!